| Basics |
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
|
| IPO Date: |
November 5, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.48B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.45 | 2.47%
|
| Avg Daily Range (30 D): |
$0.63 | 1.53%
|
| Avg Daily Range (90 D): |
$0.59 | 1.53%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.27M |
| Avg Daily Volume (30 D): |
.68M |
| Avg Daily Volume (90 D): |
.69M |
| Trade Size |
| Avg Trade Size (Sh.): |
81 |
| Avg Trade Size (Sh.) (30 D): |
54 |
| Avg Trade Size (Sh.) (90 D): |
53 |
| Institutional Trades |
| Total Inst.Trades: |
2,502 |
| Avg Inst. Trade: |
$1.69M |
| Avg Inst. Trade (30 D): |
$2.53M |
| Avg Inst. Trade (90 D): |
$2.35M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.88M |
| Avg Closing Trade (30 D): |
$3.9M |
| Avg Closing Trade (90 D): |
$3.59M |
| Avg Closing Volume: |
53.58K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-1.15
|
$-1.07
|
|
Diluted EPS
|
|
$-1.15
|
$-1.07
|
|
Revenue
|
$
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ -90.9M
|
$ -84.71M
|
|
Operating Income / Loss
|
$
|
$ -96.34M
|
$ -94.23M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ -30.87M
|
$ 18.72M
|
|
PE Ratio
|
|
|
|
|
|
|
